Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hannah Rush

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of Hepatocellular Carcinoma|January 16, 2019
Combined hepatocellular cholangiocarcinoma (cHCC-CC): an update of genetics, molecular biology, and therapeutic interventionsChara Stavraka, Hannah Rush, Paul Ross
European Journal of Cancer (Oxford, England : 1990)|November 25, 2022
Testing alternative schedules of adjuvant immune checkpoint blockers - The need for well-designed clinical trialsGauthier Bouche, Ruth Langley, Hannah Rush, et al.
Trials|January 4, 2025
Developing a knowledge transfer and exchange strategy for a clinical trials unitAnnabelle South, Berta Terré Torras, Hannah Rush, et al.
European Urology Oncology|August 21, 2024
How Can Participant Experience of Quality-of-Life Research Be Improved in Cancer Research: Views of the Patient and Public Involvement Representatives from the STAMPEDE2 Prostate Cancer TrialMinal Padden-Modi, Hannah Rush, Hoda Abdel-Aty, et al.
Therapeutic Advances in Medical Oncology|September 24, 2020
Outcomes of the 2019 novel coronavirus in patients with or without a history of cancer: a multi-centre North London experienceNalinie Joharatnam-Hogan, Daniel Hochhauser, Kai-Keen Shiu, et al.
Contemporary Clinical Trials Communications|November 18, 2024
Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and reportAngela Meade, Elena Frangou, Babak Choodari-Oskooei, et al.
Lancet (London, England)|April 7, 2024
The Lancet Commission on prostate cancer: planning for the surge in casesNicholas D James, Ian Tannock, James N'Dow, et al.
Plos Medicine|June 7, 2022
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trialChris C Parker, Nicholas D James, Christopher D Brawley, et al.
Lancet (London, England)|December 26, 2021
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocolGerhardt Attard, Laura Murphy, Noel W Clarke, et al.
The Lancet. Oncology|July 10, 2025
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocolSilke Gillessen, Laura Murphy, Nicholas D James, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Hepatocellular Carcinoma|January 16, 2019
Combined hepatocellular cholangiocarcinoma (cHCC-CC): an update of genetics, molecular biology, and therapeutic interventionsChara Stavraka, Hannah Rush, Paul Ross
European Journal of Cancer (Oxford, England : 1990)|November 25, 2022
Testing alternative schedules of adjuvant immune checkpoint blockers - The need for well-designed clinical trialsGauthier Bouche, Ruth Langley, Hannah Rush, et al.
Trials|January 4, 2025
Developing a knowledge transfer and exchange strategy for a clinical trials unitAnnabelle South, Berta Terré Torras, Hannah Rush, et al.
European Urology Oncology|August 21, 2024
How Can Participant Experience of Quality-of-Life Research Be Improved in Cancer Research: Views of the Patient and Public Involvement Representatives from the STAMPEDE2 Prostate Cancer TrialMinal Padden-Modi, Hannah Rush, Hoda Abdel-Aty, et al.
Therapeutic Advances in Medical Oncology|September 24, 2020
Outcomes of the 2019 novel coronavirus in patients with or without a history of cancer: a multi-centre North London experienceNalinie Joharatnam-Hogan, Daniel Hochhauser, Kai-Keen Shiu, et al.
Contemporary Clinical Trials Communications|November 18, 2024
Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and reportAngela Meade, Elena Frangou, Babak Choodari-Oskooei, et al.
Lancet (London, England)|April 7, 2024
The Lancet Commission on prostate cancer: planning for the surge in casesNicholas D James, Ian Tannock, James N'Dow, et al.
Plos Medicine|June 7, 2022
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trialChris C Parker, Nicholas D James, Christopher D Brawley, et al.
Lancet (London, England)|December 26, 2021
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocolGerhardt Attard, Laura Murphy, Noel W Clarke, et al.
The Lancet. Oncology|July 10, 2025
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocolSilke Gillessen, Laura Murphy, Nicholas D James, et al.
Pageof 2